<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head>
<title>Guidance for Third Parties and FDA Staff; Third Party Review of Premarket Notifications (Appendix 3A)</title>
<meta name="description" content="Guidance for Third Parties and FDA Staff; Third Party Review of Premarket Notifications">
<meta name="Posted" content="09-30-2004">
<meta name="Author" content="Eric Rechen">
<meta name="Issued" content="09-28-2004">
<meta name="keywords" content="premarket, third party review, guidance">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="cdrhguidance" content="cdrhguidance">
</head>
<body BGCOLOR="#FFFFFF">
<!-- #BeginLibraryItem "/Library/header-minimal.lbi" -->
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr> 
    <td align="center" background="/graphics/mastheadart/centers/fda_mast_bkgrd.gif"><a href="#skipheader"><img src="/cdrh/images/clearpixel.gif" width="1" height="1" border="0" alt="Skip Navigation"></a><a href="/default.htm"><img src="/graphics/mastheadart/centers/fda_mast_01.gif" alt="FDA Logo links to FDA home page" height="70" width="116" border="0"></a><img src="/graphics/mastheadart/centers/fda_cdrh_02.gif" alt="Center for Devices and Radiological Health, U.S. Food and Drug Administration" height="70" width="383" usemap="#fda_cber_02bb13509b" border="0"><a href="http://www.hhs.gov"><img src="/cdrh/images/fda_mast_03alt.gif" alt="HHS Logo links to Department of Health and Human Services website" height="70" width="116" border="0"></a></td>
  </tr>
  <tr> 
    <td bgcolor="#ffffff"> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 0.7em; text-align: center;  margin-top: 5px; margin-bottom: 5px;"><a href="/default.htm">FDA 
        Home Page</a> | <a href="/cdrh">CDRH Home Page</a> | <a href="/search.html">Search</a> 
        | <a href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/topicindex/topindx.cfm">CDRH 
        A-Z Index</a> | <a href="/cdrh/comment4.html">Contact CDRH</a> 
        <map name="fda_cber_02bb13509b">
          <area shape="rect" coords="4,16,379,44" href="/default.htm" alt="U.S. Food and Drug Administration">
          <area shape="rect" coords="8,55,374,69" href="/cdrh/index.html" alt="Center for Devices and Radiological Health">
        </map>
        <br>
        <img src="/cdrh/images/fdablackline.gif" alt="horizonal rule" width="100%" height="11" border="0"><a name="skipheader"></a></td>
  </tr>
</table>
<!-- #EndLibraryItem --> 
<h2 align="center">Guidance for Third Parties and FDA Staff<br>
  Third Party Review of Premarket Notifications</h2>
<h1 align="center">Appendix 3A: Review Memorandum Template and Instructions for 
  Assay and Instrument Combination Submissions</h1>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr> 
    <td><div align="right"><a href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfggp/search.cfm"><img src="/cdrh/images/homepg/related-info.gif" width="150" height="32"
        border="0" alt="(See Related Information)"></a> <a href="2237a3a.pdf"><img src="/cdrh/images/printerfriendly-small.gif" alt="PDF Printer Version" width="150" height="33" border="0"></a>&nbsp;</div></td>
  </tr>
</table>

<table width="100%%" border="1" cellspacing="0" cellpadding="2">
  <tr> 
    <td width="33%" bgcolor="#dddddd"><strong><a href="2237a2.html">Prev. Page: 
      Appendix 2</a></strong></td>
    <td width="33%" align="center" bgcolor="#eeeeee">Current Page: Appendix 3A</td>
    <td width="33%" align="right" bgcolor="#dddddd"><strong><a href="2237a3b.html">Next 
      Page: Appendix 3B</a></strong></td>
  </tr>
</table>
<table width="34%" border="1" align="center" cellpadding="2" cellspacing="0">
  <tr> 
    <td width="33%" bgcolor="#dddddd"><strong><a href="2237.html">Back to Main 
      Guidance Document</a></strong></td>
  </tr>
</table>
<h4> A. 510(k) Number:</h4>
<blockquote>
  <p> Indicate the 510(k) tracking number assigned to the document.</p>
</blockquote>
<h4> B. Purpose for Submission:</h4>
<blockquote>
  <p> Indicate the reason for submission of this 510(k), e.g., reagent formulation 
    changes, labeling changes, software changes.</p>
</blockquote>
<h4> C. Measurand:</h4>
<blockquote>
  <p> Identify the specific analyte to be tested.</p>
</blockquote>
<h4> D. Type of Test:</h4>
<blockquote>
  <p> State whether the test is either quantitative or qualitative. Indicate the 
    technology, e.g., ELISA, RT-PCR.</p>
</blockquote>
<h4> E. Applicant:</h4>
<blockquote>
  <p> Provide name of the sponsor.</p>
</blockquote>
<h4> F. Proprietary and Established Names:</h4>
<blockquote>
  <p> List all the proprietary and established names.</p>
</blockquote>
<h4> G. Regulatory Information:</h4>
<ol>
  <li> <u>Regulation section: </u> 
    <p>Provide the relevant Code of Federal Regulations sections for the device, 
      e.g., 21 CFR section 866.XXX, Tumor Associated Antigen Immunological Test 
      System.</p>
  </li>
  <li> 
     <u>Classification:</u><br>
      <p>State whether the device is class I, II, or III.</p>
  </li>
  <li> 
     <u>Product code:</u><br>
      <p>Indicate the specific analyte code for the device.</p>
  </li>
  <li>
     <u>Panel:</u><br>
      <p>State the regulatory panel for the device: Chemistry (75), Hematology (81), 
      Immunology (82), Microbiology (83), Pathology (88), Toxicology (91).</p>
  </li>
</ol>
<h4>H. Intended Use:</h4>
<blockquote> 
  <p>State the final version of the intended use statement, i.e., as it will appear 
    in the labeling of the device.</p>
  <ol>
    <li> <u>Intended use(s):</u>
      <p>State the specific intended use(s) for which the test will be used.</p></li>
     <li><u>Indication(s) for use:</u>
      <p>State the specific indication(s) for which the test will be used.</p></li>
      <li><u>Special conditions for use statement(s):</u>
      <p>Describe any special applications of the device (see 809.10) or specific 
      contraindications or indications for use not addressed in the Intended Use 
      Statement, if applicable, e.g., prescription use, OTC, waived, POC, home 
      use.</p></li>
    <li><u>Special instrument requirements:</u> 
      <p>
      Briefly describe any special instrument requirements for the device.</p></li>
  </ol>
</blockquote>
<h4>I. Device Description:</h4>
<blockquote>
  <p>Provide a brief description of the characteristics of the device, that is, 
    the design, model, components, etc., (i.e., the make-up of the device).</p>
</blockquote>
<h4>J. Substantial Equivalence Information:</h4>
<ol>
  <li><u> Predicate device name(s):</u><br>
    &nbsp; <br>
    In a list provide the name(s) of the legally marketed device(s) with the same 
    intended use to which substantial equivalence is (are) claimed.<br>
    &nbsp; </li>
  <li> <u>Predicate 510(k) number(s):</u><br>
    &nbsp; <br>
    In a list (in the same order as in J. 1. above) provide the 510(k) submission 
    number(s) for the predicate device(s) for which substantial equivalence is 
    (are) claimed.<br>
    &nbsp; </li>
  <li> <u>Comparison with predicate:</u><br>
    &nbsp; <br>
    Provide a side-by-side comparison of the technological and analytical characteristics, 
    for the new device and the predicate. For example, see table below:</li>
</ol>
<table width="100%%" border="1" cellspacing="0" cellpadding="2">
  <tr> 
    <th colspan="3">Similarities</td>
  </tr>
  <tr bgcolor="#eeeeee"> 
    <th width="33%">Item</th>
    <th width="33%">Device</th>
    <th width="33%">Predicate</th>
  </tr>
  <tr> 
    <td width="33%">&nbsp;</td>
    <td width="33%">&nbsp;</td>
    <td width="33%">&nbsp;</td>
  </tr>
</table>
<br>
<table width="100%%" border="1" cellspacing="0" cellpadding="2">
  <tr> 
    <th colspan="3">Differences</tr>
  <tr bgcolor="#eeeeee"> 
    <th width="33%">Item</th>
    <th width="33%">Device</th>
    <th width="33%">Predicate</th>
  </tr>
  <tr> 
    <td width="33%">&nbsp;</td>
    <td width="33%">&nbsp;</td>
    <td width="33%">&nbsp;</td>
  </tr>
</table>
<h4>K. Standard/Guidance Document Referenced (if applicable):</h4>
<blockquote>
  <p>List any recognized standards or relevant guidance referenced. Describe modification(s) 
    to recognized standards (if any).</p>
</blockquote>
<h4>L. Test Principle:</h4>
<blockquote> 
  <p>Provide a description of the technology/ methodology utilized in the device. 
    Discuss the principles of the device methodology, and indicate whether it 
    is well established or new and unproven.</p>
</blockquote>
<h4>M. Performance Characteristics (if/when applicable):</h4>
  
<blockquote> 
  <p>The type of data to be provided in this section depends on the intended use, 
    technological characteristics of the new device, and on claims made by the 
    manufacturer.</p>
</blockquote>
<ol>
  <li> <u>Analytical performance:</u> <br>
    &nbsp; 
    <ol type="a">
      <li> <em>Precision/Reproducibility: <br>
        &nbsp; </em> 
        <ol type="i">
          <li> Study design: Describe test methods. Include information such as 
            sample types tested, number of samples or measurements, target concentrations. 
            Indicate n for the parameters varied (e.g., observations, days, runs, 
            operators, sites, lots, instruments, calibration). Describe statistical 
            methods.<br>
            &nbsp; </li>
          <li> Results/Acceptance criteria: Include percent CV /Standard deviation 
            for total and within-run precision (and other parameters e.g., between-site, 
            between-instrument, where applicable).<br>
            &nbsp; </li>
        </ol>
      </li>
      <li> <em>Linearity/assay reportable range:</em> <br>
        &nbsp; 
        <ol type="i">
          <li> Study design: Describe test methods. Include information such as 
            sample types tested (e.g., unaltered patient sample, spiked or diluted 
            patient sample, spiked patient pools, control material), target concentrations 
            or range, number of samples, calculations/statistical methods. Include 
            description of the test for high dose hook effect where appropriate.<br>
            &nbsp; </li>
          <li> Results/Acceptance criteria: Identify the linear range and acceptable 
            or maximum difference from linearity within the range.<br>
            &nbsp; </li>
        </ol>
      </li>
      <li><em>Traceability, Stability, Expected values (controls, calibrators, 
        or methods):</em> 
        <p>Where applicable, briefly summarize the information about traceability 
          of calibrators and method. Include, for example, methods and acceptance 
          criteria for stability studies, traceability to reference material and 
          description of value assignment, validation, and acceptance criteria.</p>
      </li>
      <li><em> Detection limit:<br>
        &nbsp; </em> 
        <ol type="i">
          <li>Study Design: Describe the test methods. Include information such 
            as sample types tested, target concentrations/range, number of measurements, 
            statistical methods. Describe which aspects of sensitivity were measured, 
            for example: Limit of blank: usually mean of blank +2 to 3 SD, Limit 
            of detection: lowest level detected &gt; 95% of the time, Functional 
            lower limit: Lowest analyte concentration where % CV is acceptable.<br>
            &nbsp; </li>
          <li>Results/Acceptance criteria: Describe the sensitivity level for 
            each measure of sensitivity assessed.<br>
            &nbsp; </li>
        </ol>
      </li>
      <li><em>Analytical specificity:</em><br>
        &nbsp; 
        <ol type="i">
          <li>Study design: Describe test methods. Include information such as 
            sample types tested (e.g., samples spiked with interferent, samples 
            naturally high in interferent etc.), concentrations or intervals of 
            potential interferents or cross-reactants tested, and the concentration 
            of intended use analyte (if present) in the sample. Define the comparator/control 
            samples used (e.g. spiked samples containing analyte without interferent), 
            statistical methods, definitions/calculations of cross-reactivity 
            or recovery.<br>
            &nbsp; </li>
          <li>Results/Acceptance criteria: Describe any interference observed 
            (e.g., recoveries for interference levels tested). Describe any trends 
            (e.g., &quot;high levels of metabolite x may cause depressed results&quot;).<br>
            &nbsp; </li>
        </ol>
      </li>
      <li><em>Assay cut-off:</em><br>
        &nbsp;<br>
        Describe whether the cutoff was established previously in the literature 
        (and whether it was established with this specific device) or in this 
        submission. If the latter, describe the study design including methods 
        for determining the cutoff, including the population(s) studied (demographics/ 
        selection/ inclusion and exclusion criteria, number of individuals included), 
        reference method, or method of clinical diagnosis and statistical methods 
        used to generate results. Define &#8220;gray zone,&#8221; if applicable.<br>
        &nbsp;<br>
        Results: sensitivity and specificity for chosen cutoffs values. <br>
        &nbsp; </li>
    </ol>
  </li>
  <li> <u>Comparison studies:</u><br>
    &nbsp; 
    <ol type="a">
      <li><em>Method comparison with predicate device:</em><br>
        &nbsp; 
        <ol type="i">
          <li>Study design: Describe test methods. Identify the comparator(s) 
            (e.g., predicate device, reference method). Describe the sample type(s) 
            (e.g., unaltered patient specimens, spiked or diluted patient specimens, 
            spiked patient pools, and control material), matrix, number of samples, 
            sample range. When appropriate include information such as number/types 
            of sites, sample selection methods, inclusion/exclusion criteria, 
            overall demographic description of patients represented by the samples 
            (e.g., age, gender, race, how/whether samples represent the intended 
            use population), number of individuals represented. Describe statistical 
            methods used to generate results (e.g., regression methods, data exclusion, 
            number of observations represented by each data point).<br>
            &nbsp; </li>
          <li> Results: Describe overall results and/or results for specific sites 
            and patient groups, as appropriate. For quantitative tests, include 
            information such as slope and intercept (with confidence intervals), 
            correlation coefficient, measure of scatter around the regression 
            line (e.g., sy..x), measure of bias at medical decision levels. In 
            some cases, it may be helpful to include a graph (x-y graph or bias 
            plot). For qualitative or semi-quantitative tests, include percent 
            agreement with comparator for positive/negative samples, confidence 
            intervals.<br>
            &nbsp; </li>
        </ol>
      </li>
      <li><em>Matrix comparison: </em><br>
        &nbsp; 
        <ol type="i">
          <li>Study design: For each matrix in the intended use, describe the 
            method for comparison or determination of accuracy. Include information 
            such as sample types tested, number of samples, sample range or target 
            concentrations tested, and calculations/statistical methods.<br>
            &nbsp; </li>
          <li> Results/Acceptance criteria: Describe the accuracy of the new matrix 
            or results of the matrix comparison.</li>
        </ol>
      </li>
    </ol>
  </li>
  <li><u>Clinical studies:</u> <br>
    &nbsp; 
    <ol type="a">
      <li> <em>Clinical Sensitivity: </em><br>
        &nbsp; 
        <ol type="i">
          <li> Study design: Explain how &#8220;Clinical Truth&#8221; was determined. 
            Include information such as method(s) of diagnosis, specimen types, 
            patient demographics, inclusion/exclusion criteria, number of specimens 
            collected, (any discarded), number of individuals represented, number/types 
            of sites, statistical methods. When appropriate include collection 
            methods, other pertinent information.<br>
            &nbsp; </li>
          <li> Results: Sensitivity, specificity, positive and negative predictive 
            value with confidence intervals. Describe results for overall study 
            and/or for specific patient groups or sites, as appropriate. <br>
            &nbsp; </li>
        </ol>
      </li>
      <li><em>Clinical specificity: </em> 
        <p>See Section 3.a.i.</p>
      </li>
      <li> <em>Other clinical supportive data (when a. and b. are not applicable): 
        </em> <br>
        &nbsp;<br>
        Provide other clinical supporting data such as clinical monitoring data, 
        etc.<br>
        &nbsp; </li>
    </ol>
  </li>
  <li><u>Clinical cut-off: </u> 
    <p>Describe whether the cutoff was established previously in the literature 
      (and whether it was established with this specific device) or in this submission. 
      If the latter, describe the study design including methods for determining 
      the cutoff including the population(s) studied (demographics/ selection/ 
      inclusion and exclusion criteria, number of individuals included), reference 
      method, or method of clinical diagnosis and statistical methods used to 
      generate results. Define &#8220;gray zone,&#8221; if applicable.</p>
    <p>Results: sensitivity and specificity for chosen cutoffs values.</p>
  </li>
  <li> 
    <p><u>Expected values/Reference range:</u></p>
    <p>Describe whether the expected range was established in the literature (and 
      whether it was established with this specific device) or in this submission. 
      If the latter, describe the methods for determining the expected range including 
      the population(s) studied (demographics/ selection/ inclusion and exclusion 
      criteria, number of individuals), reference method or method of clinical 
      diagnosis, statistical methods. </p>
    <p>Results: Describe and define (e.g., 95th percentile) normal range values 
      for relevant populations.</p>
  </li>
</ol>
<h4>N. Instrument Name:</h4>
<blockquote>
  <p>State the name of the manufacturer and the instrument name</p>
</blockquote>
<h4>O. System Descriptions:</h4>
<ol>
  <li> <u>Modes of Operation:</u><br>
    &nbsp;<br>
    Describe modes of operation, i.e., random access, batch, stat, open tube, 
    closed tube, automatic, mode.<br>
    &nbsp; </li>
  <li> <u>Software:</u><br>
    &nbsp;<br>
    Describe the kind of software the system uses, i.e., operating system, user 
    interface, data management, communications, laboratory information system. 
    Also state whether FDA has reviewed the applicant&#8217;s Hazard Analysis 
    and Software Documentation previously.<br>
    &nbsp;</li>
  <li><u>Specimen Identification:</u><br>
    &nbsp;<br>
    Describe how specimens are identified, i.e., barcode, rack/position, instrument 
    auto numbering.<br>
    &nbsp;</li>
  <li> <u>Specimen Sampling and Handling:</u><br>
    &nbsp;<br>
    Describe how specimens are mixed (for whole blood), sampled (i.e., direct 
    open tube or closed tube piercing), and handled (e.g., manual).<br>
    &nbsp;</li>
  <li> <u>Calibration:</u><br>
    &nbsp;<br>
    Describe the calibration procedures for the system, i.e., use of whole blood 
    and commercial calibration materials.<br>
    &nbsp;</li>
  <li> <u>Quality Control (QC):</u><br>
    &nbsp;<br>
    Describe quality control procedures and use of commercial quality control 
    materials. For Point-of-Care or home-use devices, i.e., handheld meters, describe 
    any electronic QC procedures.</li>
</ol>
<h4>P. Other Supportive Instrument Performance Characteristics Data Not Covered 
  In The &#8220;Performance Characteristics&#8221; Section above:</h4>
<blockquote>
  <p> Describe any additional supporting information provided by the applicant 
    that was evaluated as part of the substantial equivalence (SE) determination.</p>
</blockquote>
<h4> Q. Proposed Labeling</h4>
<blockquote>
  <p> Indicate whether the labeling is sufficient and it satisfies the requirements 
    of 21 CFR section 809.10.</p>
</blockquote>
<h4> R. Conclusion:</h4>
<blockquote>
  <p> State the rationale for the SE decision.</p>
</blockquote>
<h4> S. Other Supportive Device and Instrument Information:</h4>
<blockquote>
  <p> Describe any additional supporting information provided by the applicant 
    that was evaluated as part of the review.</p>
</blockquote>
<h4> T. Administrative Information:</h4>
<ol>
  <li> <u>Applicant Contact Information:</u><br>
    &nbsp; <br>
    Report the mailing address and contact information of the applicant, and identify 
    the contact person responsible for the information.<br>
  </li>
  <li> <u>Review Documentation:</u><br>
    &nbsp; <br>
    Record all applicable information for the administrative record, e.g., the 
    submission chronology, phone memos, faxes, e-mails, meeting minutes, discussions 
    regarding labeling issues.</li>
</ol>
<p>&nbsp;</p>
<h4 align="center">REVIEW MEMORANDUM<br>
  ASSAY AND INSTRUMENT COMBINATION TEMPLATE</h4>
<h4><br>
  A. 510(k) Number:</h4>
<h4>B. Purpose for Submission:</h4>
<h4>C. Measurand:</h4>
<h4>D. Type of Test:</h4>
<h4>E. Applicant:</h4>
<h4>F. Proprietary and Established Names:</h4>
<h4>G. Regulatory Information:</h4>
<ol>
  <li> <u>Regulation section:<br>
    </u>&nbsp;</li>
  <li><u> Classification:<br>
    </u>&nbsp;</li>
  <li><u> Product code:<br>
    </u>&nbsp;</li>
  <li><u> Panel:</u></li>
</ol>
<h4>H. Intended Use:</h4>
<ol>
  <li><u>Intended use(s):</u><br>
    &nbsp; </li>
  <li> <u>Indication(s) for use:<br>
    </u>&nbsp;</li>
  <li><u> Special conditions for use statement(s):<br>
    </u>&nbsp;</li>
  <li><u> Special instrument requirements:</u></li>
</ol>
<h4>I. Device Description:</h4>
<h4>J. Substantial Equivalence Information:</h4>
<ol>
  <li> <u>Predicate device name(s):</u><br>
    &nbsp; </li>
  <li><u>Predicate 510(k) number(s):</u><br>
    &nbsp; </li>
  <li> <u>Comparison with predicate:</u></li>
</ol>
<table width="100%%" border="1" cellspacing="0" cellpadding="2">
  <tr> 
    <th colspan="3">Similarities </tr>
  <tr bgcolor="#eeeeee"> 
    <th width="33%">Item</th>
    <th width="33%">Device</th>
    <th width="33%">Predicate</th>
  </tr>
  <tr> 
    <td width="33%">&nbsp;</td>
    <td width="33%">&nbsp;</td>
    <td width="33%">&nbsp;</td>
  </tr>
</table>
<br>
<table width="100%%" border="1" cellspacing="0" cellpadding="2">
  <tr> 
    <th colspan="3">Differences</tr>
  <tr bgcolor="#eeeeee"> 
    <th width="33%">Item</th>
    <th width="33%">Device</th>
    <th width="33%">Predicate</th>
  </tr>
  <tr> 
    <td width="33%">&nbsp;</td>
    <td width="33%">&nbsp;</td>
    <td width="33%">&nbsp;</td>
  </tr>
</table>
<h4>K. Standard/Guidance Document Referenced (if applicable):</h4>
<h4> L. Test Principle:</h4>
<h4> M. Performance Characteristics (if/when applicable):</h4>
<ol>
  <li> <u>Analytical performance:</u><br>
    &nbsp; 
    <ol type="a">
      <li> <em>Precision/Reproducibility:<br>
        &nbsp; </em></li>
      <li><em> Linearity/assay reportable range:<br>
        &nbsp; </em></li>
      <li><em> Traceability, Stability, Expected values (controls, calibrators, 
        or methods):<br>
        &nbsp;</em></li>
      <li><em> Detection limit:<br>
        &nbsp;</em></li>
      <li><em> Analytical specificity:<br>
        &nbsp;</em></li>
      <li><em> Assay cut-off:</em><br>
        &nbsp;</li>
    </ol>
  </li>
  <li> <u>Comparison studies:</u> <br>
    &nbsp; 
    <ol type="a">
      <li> <em>Method comparison with predicate device:<br>
        &nbsp;</em></li>
      <li><em> Matrix comparison:</em><br>
        &nbsp;</li>
    </ol>
  </li>
  <li> <u>Clinical studies: </u><br>
    &nbsp; 
    <ol type="a">
      <li><em> Clinical Sensitivity:<br>
        &nbsp;</em></li>
      <li><em> Clinical specificity:<br>
        &nbsp;</em></li>
      <li><em> Other clinical supportive data (when a. and b. are not applicable):</em><br>
        &nbsp;</li>
    </ol>
  </li>
  <li><u>Clinical cut-off:</u><br>
    &nbsp;</li>
  <li><u>Expected values/Reference range: </u> </li>
</ol>
<h4>N. Instrument Name:</h4>
<h4>O. System Descriptions:</h4>
<ol>
  <li><u>Modes of Operation:</u><br>
    &nbsp; </li>
  <li> <u>Software:</u><br>
    &nbsp;<br>
    FDA has reviewed applicant&#8217;s Hazard Analysis and software development 
    processes for this line of product types:<br>
    &nbsp;<br>
    Yes ________ or No ________<br>
  </li>
  <li> <u>Specimen Identification:</u><br>
    &nbsp; </li>
  <li><u>Specimen Sampling and Handling:</u><br>
    &nbsp; </li>
  <li> <u>Calibration:</u><br>
    &nbsp; </li>
  <li> <u>Quality Control:</u></li>
</ol>
<h4> P. Other Supportive Instrument Performance Characteristics Data Not Covered 
  In The &#8220;Performance Characteristics&#8221; Section above:</h4>
<h4>Q. Proposed Labeling:</h4>
<h4>R. Conclusion:</h4>
<h4>S. Other Supportive Device and Instrument Information:</h4>
<h4>T. Administrative Information:</h4>
<ol>
  <li> <u>Applicant Contact Information: </u><br>
    &nbsp; 
    <ol type="a">
      <li> <em>Name of applicant:<br>
        &nbsp; </em></li>
      <li><em> Mailing address:<br>
        &nbsp; </em></li>
      <li><em> Phone #:<br>
        &nbsp; </em></li>
      <li><em> Fax #:<br>
        &nbsp; </em></li>
      <li><em> E-mail address (optional):<br>
        &nbsp; </em></li>
      <li><em> Contact:<br>
        &nbsp; </em></li>
    </ol>
  </li>
  <li><u> Review Documentation:</u><br>
  </li>
</ol>
<table width="34%" border="1" align="center" cellpadding="2" cellspacing="0">
  <tr> 
    <td width="33%" bgcolor="#dddddd"><strong><a href="2237.html">Back to Main 
      Guidance Document</a></strong></td>
  </tr>
</table>
<table width="100%%" border="1" cellspacing="0" cellpadding="2">
  <tr> 
    <td width="33%" bgcolor="#dddddd"><strong><a href="2237a2.html">Prev. Page: 
      Appendix 2</a></strong></td>
    <td width="33%" align="center" bgcolor="#eeeeee">Current Page: Appendix 3A</td>
    <td width="33%" align="right" bgcolor="#dddddd"><strong><a href="2237a3b.html">Next 
      Page: Appendix 3B</a></strong></td>
  </tr>
</table>
<p align="right">Updated September 30, 2004</p>
<!-- #BeginLibraryItem "/Library/footer-minimal.lbi" --><p><img src="/graphics/blkpixel.gif" alt="horizonal rule" height="1" width="100%" border="0"></p>
<p style="font-family: Arial, Helvetica, sans-serif; color: #000000; font-size: 0.7em; text-align: center;"><a href="/cdrh">CDRH Home Page</a> | <a href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/topicindex/topindx.cfm">CDRH   A-Z Index</a> | <a href="/cdrh/comment4.html">Contact CDRH</a> | <a href="http://www.hhs.gov/Accessibility.html">Accessibility</a>   | <a href="/cdrh/disclaim.html">Disclaimer<br></a><a href="/default.htm">FDA Home Page</a> | <a href="/search.html">Search   FDA Site</a> | <a href="/opacom/hpchoice.html">FDA A-Z Index</a> | <a href="/comments.html">Contact FDA</a> | <a href="http://www.hhs.gov">HHS Home Page</a></p>
<p style="font-family: Arial, Helvetica, sans-serif; color: #000000; font-size: 0.7em; text-align: center;">Center for Devices and Radiological Health / CDRH</p><!-- #EndLibraryItem --> 
</body>
</html>
